This document assesses the risk associated with the dissemination of carbapenemase-producing hypervirulent Klebsiella pneumoniae (hvKp) of sequence type (ST) 23 and other STs in the European Union/European Economic Area (EU/EEA).
The epidemiological situation of SARS-CoV-2 in humans and animals is continually evolving. To date, animal species known to transmit SARS-CoV-2 are American mink, raccoon dog, cat, ferret, hamster, house mouse, Egyptian fruit bat, deer mouse and white-tailed deer. Among farmed animals, American mink have the highest likelihood to become infected from humans or animals and further transmit SARS-CoV-2.
According to the current ECDC assessment, there is moderate probability of XBB.1.5 becoming dominant in the EU/EEA and causing a substantial increase in the number of COVID-19 cases within the next one to two months.
In recent weeks, respiratory syncytial virus (RSV) circulation in the EU/EEA has intensified, with increasing transmission rates in all population groups and an earlier-than-usual start of the season. Several EU/EEA countries are experiencing high RSV circulation and the number of severe acute respiratory infections (SARI) due to RSV is increasing. At this time of the year RSV infections are not unusual, however this year there is more RSV activity and it began earlier than in pre-COVID-19 seasons.
The primary aim of this systematic review and meta-analysis was to estimate the prevalence of symptoms of post COVID-19 condition, stratified by recruitment setting (community, hospital and Intensive Care Unit (ICU)) as a proxy for disease severity.
An increase in severe acute hepatitis cases of unknown aetiology among previously healthy children was first reported by the United Kingdom (UK) on 5 April 2022.
Italy has reported an outbreak of Candida auris in the region of Liguria with at least 277 cases. The first C. auris case in Liguria was detected in one hospital in July 2019 and cases continued to occur sporadically in the same hospital.
The SARS-CoV-2 Omicron variant of concern (VOC) is rapidly replacing SARS-CoV-2 Delta in most European Union/European Economic Area (EU/EEA) countries, and is broadly following a west-to-east progression.
The risk to public health posed by the spread of the Omicron VOC in the context of ongoing Delta VOC transmission in the EU/EEA is assessed in this update.